Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer

Seung Yeun Chung; Kyung Hwan Kim; Ki Chang Keum; Yoon Woo Koh; Se-Heon Kim; Eun Chang Choi; Chang Geol Lee

doi:10.4143/crt.2016.503

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(1); 2018 > Article

Original Article Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer: Seung Yeun Chung, MD¹, Kyung Hwan Kim, MD¹, Ki Chang Keum, MD, PhD¹, Yoon Woo Koh, MD, PhD², Se-Heon Kim, MD, PhD², Eun Chang Choi, MD, PhD², Chang Geol Lee, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(1):156-163.
DOI: https://doi.org/10.4143/crt.2016.503
Published online: March 17, 2017

¹Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

²Department of Otorhinolaryngology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

Correspondence: Chang Geol Lee, MD, PhD Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8114 Fax: 82-2-2227-7823 E-mail: cglee1023@yuhs.ac

• Received: October 19, 2016 • Accepted: March 10, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

10,025 Views
405 Download
22 Web of Science
23 Crossref
22 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The purpose of this study was to compare the treatment outcomes of definitive radiotherapy (RT) with cordectomy in patients with early glottic cancer.
Materials and Methods
A total of 165 patients who were diagnosedwith T1/2 squamous cell carcinoma of the glottic larynx between January 2006 and December 2012 were retrospectively analyzed. A total of 112 patients received RT and 53 patients received cordectomy. Local control (LC), disease-free survival (DFS), overall survival (OS), and larynx preservation rates after RT and cordectomy were investigated.
Results
The median follow-up period was 77.7 months (range, 10.7 to 127.0 months). The 3- and 5-year LC rates were 91.9% and 89.9%, respectively, for the RT group, and 82.8% and 73.2%, respectively, for the cordectomy group (p=0.006). The 3- and 5-year DFS rates were 87.5% and 83.7%, respectively, for the RT group and 79.2% and 68.0%, respectively, for the cordectomy group (p=0.046). No significant differences were identified in the 5-year OS (92.8% vs. 90.6%, p=0.713) or larynx preservation rates (98.2% vs. 97.2%, p=0.831) between groups. The major failure pattern was local failure (n=26), followed by regional (n=3) and distant failure (n=2). Multivariate analysis of LC showed that T2 stage (p=0.012) and receiving cordectomy as initial treatment (p=0.001) were significantly associated with poorer LC.
Conclusion
RT resulted in higher rates of LC and DFS compared to cordectomy for early glottic cancer. Treatment with radiotherapy is feasible and should be encouraged for both T1 and T2 glottic cancer.
Key words: Laryngeal neoplasms, Radiotherapy, Local neoplasm recurrence

Introduction

Laryngeal cancer is one of the most common head and neck malignancies. It is estimated that approximately 13,560 new laryngeal cancer cases occurred in the United States in 2015, accounting for 3,640 deaths [1]. Among laryngeal cancers, the glottic larynx is the most common subsite, being involved approximately three times more often than the supraglottic larynx. Since glottic cancer involves the vocal cord, it is often diagnosed in the early stages owing to symptoms such as hoarseness. In early glottic cancer, lymph node metastasis is rare, with an incidence of clinically positive lymph nodes of nearly zero for T1 stage and < 2% for T2 stage, and a complete cure can often be achieved [2-4]. Therefore, the goal is to achieve the best local control (LC) leading to a complete cure and optimal functional results.

At present, there are various treatment modalities for treating early glottic cancer; namely, radiotherapy (RT), cordectomy, and surgery (e.g., partial laryngectomy). Although surgery has been used for decades in the past, its use has greatly decreased in recent years because of decreasing functional results and advances in RT and cordectomy [5].

The optimal treatment for early glottic cancer has continuously been an issue of debate, primarily because of the absence of results from large prospective randomized trials [6]. Recent studies have shown similar LC between RT and cordectomy. Mendenhall et al. [7] compared various nonrandomized data and reported LC rates ranging from approximately 80% to 94% for T1 tumors and 70% to 85% for T2 tumors for both modalities [8]. In such circumstances, decisions regarding the management of early glottic cancer vary across institutions and countries [9,10]. Since there are no ongoing randomized trials or expected randomized trials in the near future, it is important to review and compare retrospective studies. In our institution, all patients visited the Department of Otorhinolaryngology (ENT) first, and those who were determined to be not adequately resectable via cordectomy by ENT surgeons were referred to the Department of Radiation Oncology.

This study was conducted to evaluate LC, disease-free survival (DFS), overall survival (OS), and larynx preservation rates after RT or cordectomy as treatment options for early glottic cancer.

Materials and Methods

1. Patients

We retrospectively reviewed the medical records of patients who were diagnosed with early stage squamous cell carcinoma of the glottic larynx between January 2006 and December 2012 in two major clinical institutes. Early stage glottic cancer was defined as stage Tis (in situ), T1-2 without nodal metastases. Patients diagnosed with double primary cancer (n=35), and patients who received treatment prior to RT or cordectomy (n=194) or received both treatments (n=39) were excluded. The remaining 165 patients were retrospectively analyzed.

All patients were diagnosed by laryngeal microsurgery biopsy and clinically staged according to the American Joint Committee on Cancer seventh edition cancer staging.

2. Treatment

Patients who were considered not adequately resectable by cordectomy were referred for RT. Of the 165 patients, a total of 112 received definitive RT. The median dose for definitive RT was 65.25 Gy (range, 58.5 to 69.75 Gy). The most commonly used dose scheme was 64 Gy in 32 fractions for T1 stage and 66 Gy in 33 fractions for T2 stage glottic cancer patients. The fractional dose was 2 Gy (n=54), 2.25 Gy (n=56), or other (n=2). Two patients grouped as other received ipsilateral vocal cord irradiation with a fractional dose of 1.8 Gy or 2.3 Gy via tomotherapy. Definitive RT was performed by conformal RT (n=105) or tomotherapy (n=7). The gross tumor was delineated as gross tumor volume (GTV). The clinical target volume (CTV) was delineated including the whole larynx. Planning target volume (PTV) was defined as the CTV plus an adequate margin to encompass the possible setting uncertainties. For patients who received conformal RT, a traditional method was used; namely, a box field with the superior border at the top of the thyroid cartilage, the inferior border at the bottom of the cricoid cartilage (for T2, one tracheal ring below the cricoid cartilage), the anterior border at a 1 cm skin flash anteriorly, and the posterior border at the anterior edge of the vertebral body. No cone down was performed in 22 patients, and the RT field was reduced to the ipsilateral vocal cord in 20 patients. For the other 63 patients, the box field size was reduced by 1 to 2 cm depending on the patient. The median cone down dose was 46 Gy (range, 36 to 54 Gy). For those who received tomotherapy, but not ipsilateral vocal cord irradiation, the initial field was the delineated PTV, after which cone down was performed to GTV plus margin after 56 Gy.

A total of 53 patients received cordectomy, which was performed by one of two modalities: transoral laser excision (n=44) or transoral robotic surgery (n=9). Cordectomy types were type I (subepithelial cordectomy, n=9), type II (subligamental cordectomy, n=10), type III (transmulscular cordectomy, n=5), type IV (total cordectomy, n=1), type V (extended cordectomy, n=1), and unknown (n=27). The type of cordectomy was determined by the physician. No patients received chemotherapy during or after treatment in either the RT or the cordectomy group.

3. Outcome evaluation

Follow-up was performed regularly in both the Departments of ENT and Radiation Oncology on an outpatient clinic basis. The follow-up schedule was 1 month after completion of treatment and every 3 months for the first year, every 6 months for 5 years, and then annually thereafter. Events of recurrence, metastasis, and toxicity were recorded during follow-up visits. All outpatient clinic reports were retrospectively reviewed in detail to identify any toxicity events.

4. Statistical analysis

The primary endpoint was LC, and secondary endpoints included DFS, OS, and larynx preservation rates. Larynx preservation was defined as preservation of the larynx without undergoing total laryngectomy. Laryngectomy types for larynx preservation such as supracricoid laryngectomy or vertical partial laryngectomy were not considered failures of larynx preservation. The cumulative probability of LC, DFS, OS, and larynx preservation rates were calculated by the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate analyses of LC were performed using Cox regression. Multivariate analysis was performed using a backward elimination approach including all of the variables.

Results

1. Patients and tumor characteristics

Patient and tumor characteristics are shown in Table 1. The median age was the same for both groups, and patient characteristics such as age, sex, tumor type, histologic grade, anterior commissure involvement, location, and smoking history were well balanced between groups (all p > 0.05). There was a significant difference between the definitive RT and cordectomy group in T stage (p=0.001). In the RT group, 90 patients (80.4%) had T1/is and 22 patients (19.6%) had T2 stage disease. However, all 53 patients (100.0%) in the cordectomy group had T1/is. There were three stage Tis patients in the RT group and eight in the cordectomy group. Tumor type also differed significantly between groups (p=0.022). While the dominant tumor type in the RT group was the exophytic type, the dominant type in the cordectomy group was the superficial type. For the cordectomy group, a total of 26 out of 53 cordectomy cases reported the status of resection margin as positive or negative, and most did not report the length of the safety margin.

2. Local control

The median follow up period was 77.7 months (range, 10.7 to 127.0 months). LC was the primary endpoint. The 3- and 5-year LC rates were 91.9% and 89.9% for the RT group and 82.8% and 73.2% for the cordectomy group, respectively (p=0.006) (Fig. 1A). Since no T2 patients received cordectomy, a subgroup analysis of only T1 glottic cancer patients was conducted. For T1 patients (n=143), the 3- and 5-year LC rates were 95.6% and 93.0%, respectively, for the RT group (n=90), and 82.8% and 73.2% for the cordectomy group (n=53) (p=0.001) (Fig. 1B). Multivariate analysis revealed that LC was adversely affected by a T stage of T2 (hazard ratio [HR], 5.36; 95% confidence interval [CI], 1.44 to 19.99; p=0.012) and cordectomy as a treatment modality (HR, 7.79; 95% CI, 2.35 to 25.87; p=0.001) (Table 2).

3. Survival

The 3- and 5-year DFS rates were 87.5% and 83.7%, respectively, for the RT group and 79.2% and 68.0%, respectively, for the cordectomy group (p=0.046) (Fig. 2). A subgroup analysis of T1 glottic cancer patients showed similar results with 3- and 5-year DFS rates of 91.9% and 87.0%, respectively, for the RT group and 75.5% and 64.8%, respectively, for the cordectomy group (p=0.007). For OS, no significant differences were identified between the 3- and 5-year OS. The 3- and 5-year OS rates were 94.6% and 92.8%, respectively, for the RT group and 94.3% and 90.6%, respectively, for the cordectomy group (p=0.713) (Fig. 3).

Two patients in the RT group and one in the cordectomy group died of disease progression. Other causes of death were a newly developed second malignancy (n=8), postoperative bleeding after salvage surgery (n=1), aspiration pneumonia (n=1), and unknown because of follow-up loss with no evidence of disease (NED) status (n=11). The newly developed second malignancies were hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, esophageal cancer, and lung cancer.

4. Patterns of failure and larynx preservation

In the definitive RT group, a total of 12 local failures, three regional failures, and one distant failure occurred. All failures occurred independently. For local failures, failure sites included the involved vocal cord. For patients with recurrent stage T1 or T2N0M0, salvage treatment modalities were cordectomy (n=4), re-irradiation (n=1), supracricoid partial laryngectomy (n=1), and none because of a second primary cancer (n=1). Among four patients who received salvage cordectomy, two were salvaged successfully, one died of lung cancer, and one died due to disease progression. For recurrent stage T3 or T4N0M0, salvage treatment modalities were total laryngectomy (n=3), supracricoid partial laryngectomy (n=1), and none because of follow-up loss (n=1). Among regional failures, two were treated with salvage neck dissection followed by postoperative RT and one was treated with salvage chemoradiotherapy. One distant failure that occurred in the T-spine was successfully salvaged by RT.

In the cordectomy group, a total of 14 local failures and one distant failure occurred. Almost all local failure sites included the ipsilateral vocal cord, except for one failure that occurred in the contralateral vocal cord. One distant failure occurred as a hilar lymph node metastasis and was treated with RT. Salvage treatment modalities performed for local recurrences were laryngeal microsurgery (n=2), vertical partial laryngectomy or supracricoid partial laryngectomy (n=3), cordectomy (n=3), RT (n=5), and none because of follow-up loss (n=1). All five patients who received salvage RT were salvaged successfully.

Larynx preservation rates showed no significant difference between the groups. For the RT group, the 3- and 5-year larynx preservation rates were 98.2%, while they were 100.0% and 97.2% in the cordectomy group (p=0.831).

5. Complications

During RT, three patients experienced a grade III skin reaction and two experienced grade III pharyngitis. Additionally, one patient required a 1-week break during treatment because of a grade III skin reaction. There were no late complications more severe than grade 2. When follow-up of the patients in the RT group was conducted in the radiation oncology department, subjective scoring of the voice quality was performed. The patient scored the voice quality in a scale of 0 to 100. The score for most patients was more than 80, but six patients (5.4%) still complained of continued hoarseness at a median of 10 months (range, 3 to 44 months) after treatment. In the cordectomy group, in one institution, patients who complained of severe voice impairment underwent assessment that included speech intelligibility and the percentage of consonants correct as criteria, which resulted in three patients being diagnosed with phonation disorder. In the other institution, voice handicap index was assessed for two-thirds of the patients who received cordectomy, and a total of six patients (11.3%) complained of moderate to severe voice impairment at a median of 13 months (range, 2 to 46 months) after cordectomy.

Discussion

In our study, the RT group had better LC and DFS than the cordectomy group, with a 5-year LC rate of 89.9% and 73.2%, and a DFS rate of 83.7% and 68.0%, respectively. In addition, multivariate analysis revealed that LC was adversely affected by T stage and cordectomy as the first treatment choice. Currently, there are variable results regarding what the optimal treatment modality for early glottic cancer is, and to the best of our knowledge, this is the first study to show favorable results for RT.

In comparison to our results, previous studies have shown different results concerning LC. O’Hara et al. [11] conducted a review of 36 publications and concluded that there was no demonstrable difference in LC between RT and transoral laser surgery. The 3-year LC rates were 89.3% and 88.9% for RT and transoral laser surgery, respectively, for stage IA tumors and 86.2% and 76.8%, respectively, for stage IB tumors [11]. Another comprehensive systemic review by Yoo et al. [6] also concluded that there is no evidence in favor of either treatment.

An Italian study of RT alone showed 3-year and 5-year LC rates of 86% and 84%, respectively, for 831 T1 glottic cancer cases. For 256 T2 glottic cancer patients, the 3-year and 5-year LC rates were both 73% [12,13]. In our study, the results were superior for T1 stage, with 3-year and 5-year LC rates of 95.6% and 93%, respectively, and 3-year and 5-year LC rates of 77.0% for both for stage T2. For cordectomy, Canis et al. [14] reported a 5-year LC rate of 86.8% for 404 patients with T1a glottic cancer who received transoral laser microsurgery. The results were inferior in our analysis, with a 5-year LC rate of 73.2% for T1 patients. Therefore, the favorable results for RT group in our study may have been due to the superior results of the RT group and the inferior results of the cordectomy group compared to previous reports.

In our study, the RT field was uniformly set for nearly all patients. The RT field generally not only included the gross tumor area but also areas concerned with microscopic extension. Cordectomy, on the other hand, has anatomical limitations that makes it difficult to expose the tumor adequately, especially with thyroid cartilage, cricothyroid membrane, and para-arytenoid musculature acting as limitations [15]. In addition, the extent of resection is always a dilemma for surgeons since resection extent is closely linked with voice quality [16]. Thus, cordectomy may not have been sufficient to control the local disease in some cases. While the results of cordectomy may vary across surgeons and institutions, when we examined whether there were any differences in LC between surgeons and the year in which cordectomy was performed, neither were found to differ significantly.

Although LC differed significantly between the RT and cordectomy groups, OS did not show any significant differences, which is consistent with the results of other studies [6]. A total of 26 local failures, three regional failures, and one distant failure occurred, but only three patients died of disease progression, demonstrating that recurrent glottic cancer could be salvaged in most cases in both treatment groups.

As for laryngeal preservation, there are various results reporting that there are no differences between the two treatments, or that the likelihood of laryngeal preservation may be higher with cordectomy [6-8]. Our results showed high rates of 5-year larynx preservation in both groups that did not differ significantly, with 98.2% and 97.2% being observed for the RT and cordectomy groups, respectively.

Since disease control rates of early glottic cancer are good with both treatment modalities, quality of voice is an essential concern. Aaltonen et al. [17] reported the first randomized study concerning voice quality of early laryngeal cancer patients. Patients who received RT or transoral laser surgery had similar overall voice quality, but RT resulted in a less breathy voice [17]. Others reported that voice quality was better in the RT group [18,19]. In our study, although there were limitations for the assessment of voice quality, there were more patients with severe voice impairments in the cordectomy group.

An interesting exception in the RT group was the two patients who received ipsilateral cord irradiation via tomotherapy, which is a modality attracting increasing interest with favorable results for both tumor control and promising voice quality [16]. These two patients have been followed up until now with NED status at 89.1 and 70.4 months, respectively. In addition, the fact that almost all local recurrences occurred at the ipsilateral vocal cord supports the possibility of treating only the ipsilateral vocal cord.

There are several limitations to our study, including its retrospective nature. In addition, objective voice quality assessment was not performed for all patients during follow-up. Thus, it is challenging to determine if one treatment modality is superior to another with respect to voice quality, which is an important factor in the decision about early glottic cancer treatment. Furthermore, the resection margins of specimens from cordectomy were not reported in many cases, making it difficult to confirm the cause of the lower LC in the cordectomy group.

However, to the best of our knowledge, this is the first study to demonstrate favorable results of RT over cordectomy. Currently, there are no prospective randomized trials and none are expected in the future; thus, decisions must be based on nonrandomized data. Most previous data show similar control rates of early glottic cancer for RT and cordectomy, and in some, a lower control rate for RT [6,11,20]. Since cordectomy outcomes can be influenced by many factors, including those associated with the location and surgeon, results may vary among studies.

In contrast to cordectomy, the favorable results of RT can be explained by unvarying inclusion of the tumor area in the RT field. Moreover, patients in the RT group did not experience any severe acute or late complications, and all but six patients (5.4%) recovered voice quality. Thus, it seems reasonable that RT should be encouraged in both T1 and T2 glottic cancer, while cordectomy should be encouraged in adequately excisable cases of early glottic cancer.

RT resulted in higher rates of LC and DFS compared to cordectomy for early glottic cancer (T1/2), with low complication rates and acceptable voice quality. Treatment with radiotherapy is feasible and should be encouraged for both T1 and T2 glottic cancer.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Kaplan-Meier estimates of local control for T1 and T2 glottic cancer (A) and Kaplan-Meier estimates of local control for T1 glottic cancer (B). RT, radiotherapy.

Fig. 2.

Kaplan-Meier estimates of disease-free survival. RT, radiotherapy.

Fig. 3.

Kaplan-Meier estimates of overall survival. RT, radiotherapy.

Table 1.

Patient and tumor characteristics

Characteristic	Total (n=165)	Definitive RT (n=112)	Cordectomy (n=53)	p-value
Age, median (range, yr)	63 (37-87)	64 (37-87)	64 (39-83)	0.260
Sex
Male	152 (92.1)	104 (92.9)	48 (90.6)	0.610
Female	13 (7.9)	8 (7.1)	5 (9.4)
Clinical T stage
T1/is	143 (86.7)	90 (80.4)	53 (100)	0.001
T2	22 (13.3)	22 (19.6)	0
Tumor type
Superficial	54 (32.7)	30 (26.8)	24 (45.3)	0.022
Exophytic	89 (53.9)	69 (61.6)	20 (37.7)
Ulcerative	15 (9.1)	10 (8.9)	5 (9.4)
Unknown	7 (4.2)	3 (2.7)	4 (7.5)
Histologic grade
NOS	46 (27.9)	27 (24.1)	19 (35.8)	0.253
Well	69 (41.8)	48 (42.9)	21 (39.6)
Moderate	46 (27.9)	33 (29.5)	13 (24.5)
Poor	4 (2.4)	4 (3.6)	0
AC involvement
Not involved	112 (67.9)	74 (66.1)	38 (71.7)	0.639
Involved	52 (31.5)	37 (33.0)	15 (28.3)
Unknown	1 (0.6)	1 (0.6)	0
Location
Both/AC involvement	55 (33.3)	41 (36.6)	14 (26.4)	0.195
Unilateral	110 (66.7)	71 (63.4)	39 (73.6)
Smoking history
Yes	107 (64.8)	72 (64.3)	35 (66.0)	0.826
No	58 (35.2)	40 (35.7)	18 (34.0)

Values are presented as number (%). RT, radiotherapy; is, in situ; NOS, not otherwise specified; AC, anterior commissure.

Table 2.

Multivariate Cox regression model for local recurrence

Variable	Univariate			Multivariate
Variable	HR	95% CI	p-value	HR	95% CI	p-value
Age (< 65 yr:≥ 65 yr)	1.45	0.67-3.14	0.342	-	-	-
Sex (male:female)	0.94	0.22-3.99	0.936	-	-	-
T stage (T1/is:T2)	2.05	0.82-5.11	0.123	5.36	1.44-19.99	0.012
Tumor type (superficial:exophytic/ulcerative)	1.60	0.63-4.03	0.320	3.39	0.95-12.13	0.061
Histologic grade (WD:MD/PD)	0.88	0.36-2.14	0.769	-	-	-
AC involvement (no:yes)	1.67	0.77-3.64	0.197	-	-	-
Location (both/AC involvement:unilateral)	0.66	0.30-1.43	0.288	-	-	-
Smoking history (no:yes)	1.27	0.55-2.91	0.580	-	-	-
Treatment (radiotherapy:cordectomy)	2.83	1.31-6.14	0.008	7.79	2.35-25.87	0.001

HR, hazard ratio; CI, confidence interval; is, in situ; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; AC, anterior commissure.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. Article PubMed
2. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
3. Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19:4029–36. Article PubMed
4. Karatzanis AD, Psychogios G, Zenk J, Waldfahrer F, Hornung J, Velegrakis GA, et al. Comparison among different available surgical approaches in T1 glottic cancer. Laryngoscope. 2009;119:1704–8. Article PubMed
5. Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol. 2009;266:1333–52. Article PubMed
6. Yoo J, Lacchetti C, Hammond JA, Gilbert RW; Head and Neck Cancer Disease Site Group. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: a systematic review. Head Neck. 2014;36:1807–19. Article PubMed
7. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100:1786–92. Article PubMed
8. Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F. Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head Neck. 2012;34:23–33. Article PubMed
9. Makki FM, Williams B, Rajaraman M, Hart RD, Trites J, Brown T, et al. Current practice patterns in the management of glottic cancer in Canada: results of a national survey. J Otolaryngol Head Neck Surg. 2011;40:205–10. PubMed
10. O'Sullivan B, Mackillop W, Gilbert R, Gaze M, Lundgren J, Atkinson C, et al. Controversies in the management of laryngeal cancer: results of an international survey of patterns of care. Radiother Oncol. 1994;31:23–32. Article PubMed
11. O’Hara J, Markey A, Homer JJ. Transoral laser surgery versus radiotherapy for tumour stage 1a or 1b glottic squamous cell carcinoma: systematic review of local control outcomes. J Laryngol Otol. 2013;127:732–8. Article PubMed
12. Frata P, Cellai E, Magrini SM, Bonetti B, Vitali E, Tonoli S, et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys. 2005;63:1387–94. Article PubMed
13. Cellai E, Frata P, Magrini SM, Paiar F, Barca R, Fondelli S, et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys. 2005;63:1378–86. Article PubMed
14. Canis M, Ihler F, Martin A, Matthias C, Steiner W. Transoral laser microsurgery for T1a glottic cancer: review of 404 cases. Head Neck. 2015;37:889–95. Article PubMed
15. Davis RK, Jako GJ, Hyams VJ, Shapshay SM. The anatomic limitations of CO2 laser cordectomy. Laryngoscope. 1982;92(9 Pt 1):980–4. Article PubMed
16. Mendelsohn AH, Xuan Y, Zhang Z. Voice outcomes following laser cordectomy for early glottic cancer: a physical model investigation. Laryngoscope. 2014;124:1882–6. Article PubMed PMC
17. Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Makitie A, Rihkanen H, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:255–60. Article PubMed
18. Arias F, Arraras JI, Asin G, Uzcanga MI, Maravi E, Chicata V, et al. Quality of life and voice assessment in patients with early-stage glottic cancer. Head Neck. 2015;37:340–6. Article PubMed
19. Laoufi S, Mirghani H, Janot F, Hartl DM. Voice quality after treatment of T1a glottic cancer. Laryngoscope. 2014;124:1398–401. Article PubMed
20. Brady JS, Marchiano E, Kam D, Baredes S, Eloy JA, Park RC. Survival impact of initial therapy in patients with T1-T2 glottic squamous cell carcinoma. Otolaryngol Head Neck Surg. 2016;155:257–64. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Particular aspects of laser microsurgery in malignant and premalignant glottic lesions
Mihai Tușaliu, Costinel Adrian Vrejoiu, Iulia Tiţă, Mădălina Vulpe, Adriana Lozbă, Cristian Bucur
ORL.ro.2024; 1(62): 9. CrossRef
Oncological outcomes of surgical management for T2N0M0 glottic laryngeal squamous cell carcinoma
Jian Zhou, Cheng‐Zhi Xu, Xiao‐Ke Zhu, Yue Yang, Liang Zhou, Hong‐Li Gong, Lei Tao
World Journal of Otorhinolaryngology - Head and Neck Surgery.2024;[Epub] CrossRef
The association between initiation weekday of radiotherapy and local control in stage 1 glottic carcinoma: a retrospective analysis
Masashi Endo, Satoru Takahashi, Yukiko Fukuda, Kohei Okada, Kazunari Ogawa, Michiko Nakamura, Masahiro Kawahara, Keiko Akahane, Eri Murakami, Chiaki Shibayama, Ryutaro Onaga, Takafumi Nagatomo, Takeharu Kanazawa, Hiroshi Nishino, Harushi Mori, Katsuyuki S
Journal of Radiation Research.2024; 65(6): 798. CrossRef
The Same–Up–Down Staging System for Recurrent Early Glottic Cancer
Giuseppe Licci, Luca Giovanni Locatello, Giandomenico Maggiore, Flavia Cozzolino, Saverio Caini, Oreste Gallo
Cancers.2023; 15(3): 598. CrossRef
Kehlkopfteilresektion – eine interdisziplinäre Gratwanderung zwischen Resektion und Funktionserhalt
Manuel Christoph Ketterer, Rainer Beck, Matthias Cohnen, Andreas Knopf
best practice onkologie.2023; 18(5): 184. CrossRef
Intensity-Modulated Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx: A Systematic Review and Meta-Analysis
Niema B. Razavian, Ralph B. D'Agostino, Rachel F. Shenker, Ryan T. Hughes
International Journal of Radiation Oncology*Biology*Physics.2023; 117(3): 652. CrossRef
Clinical Analysis of the Treatment Outcomes of Laryngeal Cancer
Takashi Kurita, Shun-ichi Chitose, Takeharu Ono, Mioko Fukahori, Shintaro Sueyoshi, Ryota Mihashi, Toshihiko Kawaguchi, Akira Hiraki, Hirohito Umeno
Practica oto-rhino-laryngologica. Suppl..2023; 163: 89. CrossRef
Comparison of Survival Outcomes of Different Treatment Options for cT1-2, N0 Glottic Carcinoma: A Propensity Score–Weighted Analysis
Qi-wei Liang, Liang Peng, Jing Liao, Chun-xia Huang, Wei-ping Wen, Wei Sun
Frontiers in Surgery.2022;[Epub] CrossRef
Survival study in early stages of glottis cancer, stratified by treatment
Yolanda Lois-Ortega, Fernando García-Curdi, Héctor Vallés-Varela, Ana Muniesa-del Campo
Acta Oto-Laryngologica.2022; 142(7-8): 627. CrossRef
Selective local postoperative radiotherapy for T3–T4 N0 laryngeal cancer
Meltem Dağdelen, Merve Şahin, Tuba Kurt Çatal, Halil Cumhur Yıldırım, Songül Çavdar Karaçam, Kimia Çepni, Ömer Erol Uzel
Strahlentherapie und Onkologie.2022; 198(11): 1025. CrossRef
Long-term impact of smoking cessation on new glottic cancer events in patients with early glottic cancer
Min-Su Kim, Hong-Gyun Wu, Myung-Whun Sung, Tack-Kyun Kwon
Acta Otorhinolaryngologica Italica.2022; 42(6): 525. CrossRef
Diode Laser for Laryngeal Cancer: “980 nm” and Beyond the Classic CO2
Petros D. Karkos, Ioannis Koskinas, Marios Stavrakas, Stefanos Triaridis, Jannis Constantinidis
Ear, Nose & Throat Journal.2021; 100(1_suppl): 19S. CrossRef
Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients
Ruichen Li, Qi Wang, Li Yan, Yi Zhu, Shengzi Wang, Shu Tian
Oral Oncology.2021; 116: 105230. CrossRef
Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients
Gerhard Dyckhoff, Rolf Warta, Christel Herold-Mende, Elisabeth Rudolph, Peter K. Plinkert, Heribert Ramroth
Cancers.2021; 13(7): 1601. CrossRef
Age as Indicator in the Selection of Surgery Modalities in Early Glottic Cancer
Jialing Wu, Kaiyun You, Xingsheng Qiu, Ting Shen, Juanjuan Song, Changlong Chen, Yanhui Jiang, Yimin Liu
Risk Management and Healthcare Policy.2021; Volume 14: 3223. CrossRef
Feasibility of single vocal cord irradiation as a treatment strategy for T1a glottic cancer
Seung Yeun Chung, Chang Geol Lee
Head & Neck.2020; 42(5): 854. CrossRef
Radiotherapy versus laser microsurgery in the treatment of early glottic cancer
Yolanda Lois-Ortega, Fernando García-Curdi, José Miguel Sebastián-Cortés, Félix De Miguel-García, Héctor Vallés-Varela, Ana Muniesa-del Campo
Acta Oto-Laryngologica.2020; 140(11): 954. CrossRef
Radiotherapy Versus Surgery–Which Is Better for Patients With T1-2N0M0 Glottic Laryngeal Squamous Cell Carcinoma? Individualized Survival Prediction Based on Web-Based Nomograms
Yajing Du, Shali Shao, Minghe Lv, Yi Zhu, Li Yan, Tiankui Qiao
Frontiers in Oncology.2020;[Epub] CrossRef
Comparison between radiotherapy and transoral laser microsurgery treatments in early-stages of glottis cancer: A five-year follow-up study
Javier Santabárbara
Investigación Clínica.2020; 61(4): 324. CrossRef
Prospective validation of an institutional treatment strategy for T1N0M0 glottic carcinoma
Simon Beyaert, Marc Hamoir, Aline Van Maanen, Vincent Grégoire, Sandra Schmitz
European Journal of Surgical Oncology.2019; 45(7): 1188. CrossRef
Prognostic factors in patients with T1 glottic cancer treated with radiotherapy
A. Mucha-Małecka, A. Chrostowska, K. Urbanek, K. Małecki
Strahlentherapie und Onkologie.2019; 195(9): 792. CrossRef
Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature
Martine Hendriksma, Elisabeth V. Sjögren
Cancers.2019; 11(9): 1234. CrossRef
Treatment of early-stage laryngeal cancer: A comparison of treatment options
Brandon Jackson Baird, C. Kwang Sung, Beth M. Beadle, Vasu Divi
Oral Oncology.2018; 87: 8. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer

Cancer Res Treat. 2018;50(1):156-163. Published online March 17, 2017

DOI: https://doi.org/10.4143/crt.2016.503

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer

Fig. 1. Kaplan-Meier estimates of local control for T1 and T2 glottic cancer (A) and Kaplan-Meier estimates of local control for T1 glottic cancer (B). RT, radiotherapy.

Fig. 2. Kaplan-Meier estimates of disease-free survival. RT, radiotherapy.

Fig. 3. Kaplan-Meier estimates of overall survival. RT, radiotherapy.

Fig. 1.

Fig. 2.

Fig. 3.

Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer

Characteristic	Total (n=165)	Definitive RT (n=112)	Cordectomy (n=53)	p-value
Age, median (range, yr)	63 (37-87)	64 (37-87)	64 (39-83)	0.260
Sex
Male	152 (92.1)	104 (92.9)	48 (90.6)	0.610
Female	13 (7.9)	8 (7.1)	5 (9.4)
Clinical T stage
T1/is	143 (86.7)	90 (80.4)	53 (100)	0.001
T2	22 (13.3)	22 (19.6)	0
Tumor type
Superficial	54 (32.7)	30 (26.8)	24 (45.3)	0.022
Exophytic	89 (53.9)	69 (61.6)	20 (37.7)
Ulcerative	15 (9.1)	10 (8.9)	5 (9.4)
Unknown	7 (4.2)	3 (2.7)	4 (7.5)
Histologic grade
NOS	46 (27.9)	27 (24.1)	19 (35.8)	0.253
Well	69 (41.8)	48 (42.9)	21 (39.6)
Moderate	46 (27.9)	33 (29.5)	13 (24.5)
Poor	4 (2.4)	4 (3.6)	0
AC involvement
Not involved	112 (67.9)	74 (66.1)	38 (71.7)	0.639
Involved	52 (31.5)	37 (33.0)	15 (28.3)
Unknown	1 (0.6)	1 (0.6)	0
Location
Both/AC involvement	55 (33.3)	41 (36.6)	14 (26.4)	0.195
Unilateral	110 (66.7)	71 (63.4)	39 (73.6)
Smoking history
Yes	107 (64.8)	72 (64.3)	35 (66.0)	0.826
No	58 (35.2)	40 (35.7)	18 (34.0)

Variable	Univariate			Multivariate
Variable	HR	95% CI	p-value	HR	95% CI	p-value
Age (< 65 yr:≥ 65 yr)	1.45	0.67-3.14	0.342	-	-	-
Sex (male:female)	0.94	0.22-3.99	0.936	-	-	-
T stage (T1/is:T2)	2.05	0.82-5.11	0.123	5.36	1.44-19.99	0.012
Tumor type (superficial:exophytic/ulcerative)	1.60	0.63-4.03	0.320	3.39	0.95-12.13	0.061
Histologic grade (WD:MD/PD)	0.88	0.36-2.14	0.769	-	-	-
AC involvement (no:yes)	1.67	0.77-3.64	0.197	-	-	-
Location (both/AC involvement:unilateral)	0.66	0.30-1.43	0.288	-	-	-
Smoking history (no:yes)	1.27	0.55-2.91	0.580	-	-	-
Treatment (radiotherapy:cordectomy)	2.83	1.31-6.14	0.008	7.79	2.35-25.87	0.001

Table 1. Patient and tumor characteristics

Values are presented as number (%). RT, radiotherapy; is, in situ; NOS, not otherwise specified; AC, anterior commissure.

Table 2. Multivariate Cox regression model for local recurrence

HR, hazard ratio; CI, confidence interval; is, in situ; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; AC, anterior commissure.